Adriamycin inhibits glycolysis through downregulation of key enzymes in Saccharomyces cerevisiae
- 2 January 2021
- journal article
- research article
- Published by Springer Nature in 3 Biotech
- Vol. 11 (1) , 1-13
Abstract
Adriamycin is a widely used drug for the treatment of various types of cancers, but its clinical application is limited because of irreversible dilated cardiomyopathy. The incidence of cardiomyopathy is a consequence of disrupted energy production, which could be related to the defects in glycogen, lipid and mucopolysaccharide metabolism. We explored the effect of Adriamycin on enzymes involved in glycolysis and apoptotic genes through molecular docking. We used Saccharomyces cerevisiae as model organism and studied the effect of Adriamycin on selected enzymes involved in glycolysis. The docking studies revealed that Adriamycin interacts with phosphofructokinase and enolase in an efficient manner. In phosphofructokinase, Adriamycin binds at the active site and with enolase the drug interacts at the cofactor-binding site (Mg2+) which might impair the activity of the enzyme. Gene expression studies revealed that Adriamycin causes the dysregulation of glycolysis through dysregulation of hexokinase, phosphoglycerate mutase, enolase and downregulation of pyruvate kinase. The drug shows a biphasic effect on the expression of genes enolase and pyruvate kinase. The impairment in glycolysis might reduce the ATP synthesis, and the cells might be deprived of energy. The condition is further worsened by elevated ROS levels triggering the cell to undergo apoptosis evidenced by downregulation of SOD and upregulation of BAX and caspase. In conclusion, our study reveals that Adriamycin impairs glycolysis and cause cell to undergo apoptosis due to oxidative stress in yeast cells.Keywords
Funding Information
- Council of Science and Technology, U.P. (EMR/2016/003548)
This publication has 39 references indexed in Scilit:
- Cardiac Metabolism in Heart FailureCirculation Research, 2013
- Persistent Overexpression of Phosphoglycerate Mutase, a Glycolytic Enzyme, Modifies Energy Metabolism and Reduces Stress Resistance of Heart in MicePLOS ONE, 2013
- An NQO1-Initiated and p53-Independent Apoptotic Pathway Determines the Anti-Tumor Effect of Tanshinone IIA against Non-Small Cell Lung CancerPLOS ONE, 2012
- Molecular Modeling Evaluation of Non‐Steroidal Aromatase Inhibitors†Chemical Biology & Drug Design, 2012
- Yeast: An Experimental Organism for 21st Century BiologyGenetics, 2011
- Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell deathBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Phosphofructo-1-Kinase Deficiency Leads to a Severe Cardiac and Hematological Disorder in Addition to Skeletal Muscle GlycogenosisPLOS Genetics, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Dynamics of Glycolytic Regulation during Adaptation of Saccharomyces cerevisiae to Fermentative MetabolismApplied and Environmental Microbiology, 2008
- Effects of doxorubicin on cardiomyocytes with reduced level of superoxide dismutaseLife Sciences, 1995